In this application note, in collaboration with C4 Therapeutics, Inc., we show how the Fida 1 can provide a full characterization of the ternary complex and its subunits, including Kds of all binding partners, sizes of subunits and the ternary complex, as well as simple integrity control. 

This application note is developed in close collaboration with C4 Therapeutics, Inc. who ispioneering a new class of small molecule drugs that selectively destroy disease-causingproteins via degradation using the innate machinery of the cell.

A link to download the Application Note will be sent to the provided e-mail immediately after submitting the form below.